Thromboembolic complications are the second leading cause of death in cancer patients. In contrast to the large body of literature on venous thromboembolism (VTE), relatively few reports have focused on the pathogenesis, incidence, management and outcomes of arterial thromboembolic events in patients with malignancy. The purpose of this article is to review the current literature on the etiology, mechanisms, and prognosis of arterial thromboembolic events in cancer patients and outline appropriate screening and management guidelines that may help lower the rates of morbidity and mortality related to these events.
Introduction
Peripheral artery disease and cancer are prevalent condi tions that often coexist. Thromboembolic complications are the second leading cause of death in cancer patients. 1 In contrast to the large number of studies on venous throm boembolism (VTE), relatively few reports have focused on the pathogenesis, incidence, management and outcomes of arterial ischemic events in patients with malignancy. The annual incidence of these events in cancer patients is not well studied. Prevalence is in the range of 1.5-3.1%. 2, 3 Multifactorial mechanisms have been implicated and the outcome following these events is poor. 4 Acute limb ischemia in patients with cancer carries a high mor tality rate. 2, 4 In a cohort study by El Sakka et al., 50% of all patients presenting to an institution with critical limb ischemia and malignancy died within 6 months, compared with 20.6% of patients without underlying malignancy. 5 The purpose of this review is to describe the etiology and mechanisms of arterial thromboembolic events in cancer patients and outline appropriate screening and manage ment guidelines that may help lower the rates of morbidity and mortality related to these events.
Epidemiology
Hypercoagulable states associated with malignancy or certain hematological disorders can present with diverse clinical ischemic syndromes. This includes venous and arterial thromboembolic events. In contrast to VTE, most of the available data regarding arterial ischemic events is based on case series and reports. Very few epidemiologic studies looked at the prevalence of arterial thromboembolic events in this patient population. Khorana et al. reported a prevalence rate of 1.5-3.1%. 2, 3 There has been a 124% increase in reported similar events from 1995 to 2002, 2 likely related to improved detection of such events and improved survival of patients with cancer. The presence of comorbidities including pulmonary disease, renal disease, infection, blood transfusion, chemotherapy and obesity are associated with a higher risk of arterial events. There is no observed difference in incidence between subgroups divided by type of malignancy and presence or absence of metastatic disease. Reported events included acute coro nary syndrome, stroke and peripheral artery thromboembo lism. 2 Schattner and colleagues reported a prevalence rate of 0.65% of peripheral arterial events in a population of 311 patients with pancreatic cancer. 6 El Sakka et al. on the other hand studied 192 consecutive patients presenting with critical limb ischemia and reported the presence of occult malignancy in 22 patients (11.5%). 5
Etiology and pathophysiology
Acute ischemic arterial events can have thrombotic or embolic etiologies. The two causes have different diagnostic and therapeutic approaches; however, the exact mechanism can sometimes be difficult to establish.
Hypercoagulability
In addition to the typical causes of arterial ischemia related to traditional cardiovascular conditions, patients with under lying malignancy or hematologic disorders have added risks for in situ thrombosis related to the inherent thrombophilia associated with their malignancy and its therapy ( Table 1) . Malignancy is a common cause of acquired thrombophilia. 7 Complex mechanistic etiologies have been implicated in this process; however, a key initiating factor is the release of procoagulants such as tissue factor and cancer proco agulant, which activate factor X and the clotting cascade. 8, 9 Inflammatory cytokines secreted by tumor cells lead to endothelial dysfunction and prime the vascular endothelium into a prothrombotic state. 10, 11 Patients with malignancy also have increased levels of clotting factors (fibrinogen, factors V, VIII, IX, XII), [12] [13] [14] thrombocytosis, impaired fibrinolytic activity, 15 and decreased protein C and S levels. [16] [17] [18] [19] Antiphospholipid antibody syndrome (APLS) is diag nosed on the basis of thrombosis in the presence of anticar diolipin antibodies, lupus anticoagulant and/or an antibeta 2 glycoprotein I antibody. 20 Zuckerman et al. reported that 21.8% of their patients with malignancies were positive for anticardiolipin antibodies (the most common type of antiphospholipid antibodies -APL), compared to 3.4% in the control group; similarly, 27.7% of the anticardiolipin positive patients experienced thromboembolic events, com pared to 14.2% of the anticardiolipinnegative patients (p < 0.05). 21 In recent years, a higher prevalence of APL has been found in patients with solid tumors compared to controls. 22 Research has suggested that these antibodies are produced in response to tumor antigens rather than secreted from the tumor cells themselves and that the antibodies are involved in the production of monoclonal immunoglobulin that might have lupus anticoagulant and anticardiolipin activities. 23 Adequate longterm management depends on accurate diag nosis, as these patients may benefit from longterm therapy with vitamin K antagonists. While screening for hypercoag ulability in cancer patients with VTE is controversial and rarely needed, those patients that present with arterial thromboembolic events without an obvious source or clear etiology, it may be warranted to assess for APLS since the longterm management is clearly altered with anticoagula tion in this situation.
Thromboembolic events
Nonbacterial thrombotic endocarditis (NBTE), tumorcell emboli and paradoxical embolus from deep venous throm bosis (DVT) through a patent foramen ovale are typical examples of embolic etiologies in these patients. NBTE is characterized by the presence of sterile plateletfibrin vege tations on the contact margins of cardiac valvular leaflets. A majority of patients presenting with NBTE are found to have cancer, and the vegetations are thought to form as a result of focal valvular endothelial injury associated with the hypercoagulability of cancer. 24 These vegetations can cause arterial thromboembolic events after dislodgement, lead ing to strokes, splenic infarctions and acute limb ischemia. Hagmann et al. reported NBTE in 4% of all patients with cancer in their study population. 25 Dutta et al. reported an 18% prevalence of NBTE in their cohort of patients with active cancer. 26 Transesophageal echocardiography is the preferred imaging modality in this setting and treatment includes lowmolecularweight heparin or unfractionated heparin (UFH) 27 (Figure 1 ). Paradoxical embolization is another mechanism that is typically detected on the basis of the concomitant presence of arterial and venous thrombosis; this finding should trigger evaluation for patent foramen ovale or atrial septal defect responsible for intracardiac righttoleft shunt (RLS). Iguchi et al. reported RLS in 55% of their cohort of cancer patients presenting with ischemic stroke. 28 They also reported that over 50% of these patients with RLS had underlying DVT or pulmonary embolisms. Diagnostic modalities for parado xical embolization include contrasttranscranial Doppler imaging, contrast transthoracic echocardiography or trans esophageal echocardiography. Systemic anticoagulation is preferred in this setting; 29 however, patent foramen ovale closure is an attractive option for recurrent events despite anticoagulation ( Figure 2 ).
Other causes of arterial ischemia
Several other mechanisms can lead to arterial ischemic events in patients with malignancy. For example, the risk of coronary artery thrombosis is two to five times higher in cancer patients with known atherosclerotic disease who are undergoing chest radiation therapy. 30 Other potential predis posing factors include chronic deconditioning resulting in immobility and mechanical compression of blood vessels by the neoplastic process or endothelial damage caused by iatrogenic mechanisms related to blood vessel catheteriza tion, surgery and chemotherapeutic agents. [16] [17] [18] [19] Lowflow states and shock associated with sepsis secondary to cancer mediated or chemotherapyinduced immunosuppression can lead to vascular stasis, arterial thrombosis and limb ischemia, especially in the presence of underlying obstructive athero sclerotic disease and hypercoagulability. Management is typically focused on reversing the lowflow state. 31 Table 2 lists some causes of arterial thromboembolic events associated with malignancy, hematologic disorders or can cer therapy.
Arterial ischemic events associated with specific malignancies

Acute leukemia
Although acute leukemia is classically associated with hem orrhagic complications, the disease course can be compli cated by thrombotic events, the incidence of which depends upon the type of leukemia and the chosen therapy. De Stefano et al. reported a 9.6% incidence of thrombosis at the time of presentation in patients with acute promyelocytic leukemia and a 1.4% incidence in patients with acute lym phocytic leukemia (ALL). 32 The incidence was reported to increase to 10.6% with lasparaginase treatment for ALL. In this study, more than 50% of the thrombotic events occurred as the presenting manifestation before cytoreductive therapy was started, with 20% of these events involving an arterial bed. 32 Mechanisms for thrombosis in acute leukemia include increased fractional volume of leukocytes, reduced cell deformability, 33, 34 increased blast cell secretion of tumor necrosis factor alpha (TNFa) and interleukin1 beta (IL1b) and subsequent induction of endothelial tissue factor expres sion, 35 and thrombomodulin downregulation and adhesion molecule upregulation. 36 Therapeutic options include leu kapheresis and immediate chemotherapy. Surgical thrombo embolectomy should be considered for large vessel occlusion ( Figure 3 ).
Myeloproliferative disorders
Clinical vascular events in myeloproliferative disorders (MPDs), such as polycythemia vera (PV) and essential thrombocythemia (ET), are characterized by microcircu latory disturbances 37 responsible for forming platelet and fibrin plugs in terminal arterial coronary, cerebral, cuta neous and peripheral circulatory beds, leading to visual and aural symptoms, intractable headaches, Raynaud's phenomenon, ischemic cerebrovascular accidents and acute coronary syndromes. 38, 39 Various studies have reported the incidence of thrombosis upon PV and ET diagnosis at 9.7-38.6%, with 64-96.7% of these events involving the arterial bed. 37 Others have reported the tendency for throm bophilia to manifest 5-6 years before an MPD diagnosis. 40 Pathophysiologic mechanisms of thrombosis in MPDs include the effects of erythrocytosis 41 and thrombocyto sis; 42 biochemical changes in the red blood cell (RBC) membrane such as JAK2dependent phosphorylation of the Lutheran blood group, leading to increased cellular adhe siveness; 43 increased plasma levels of bthromboglobulin and platelet factor 4, leading to increased platelet activa tion; 37 leukocytosis; and increased leukocyte alkaline phos phatase and intracellular elastase. 44 Thrombotic prevention in MPD patients warrants the use of aspirin, which has been demonstrated to significantly lower the risk of cardio vascular events. 45 In symptomatic patients and in those with platelet counts greater than 600,000, hydroxyurea, 46 anagrelide and/or phlebotomy appear to have some clinical benefit ( Figure 4 ). 47, 48 
AL-Amyloidosis
Lightchain amyloidosis (AL) is a monoclonal plasma cell dyscrasia in which secreted immunoglobulin is deposited in many organs including the heart. ALamyloid can occur in association with multiple myeloma, Waldenström's macroglobulinemia or nonHodgkin's lymphoma. Cardiac involvement in the form of intracardiac thrombosis and thromboembolic events is found in 26-33% patients with pri mary amyloidosis, particularly the immunocytederived (AL) type, despite a preserved left ventricular ejection fraction and the absence of cardiac arrhythmias. 49, 50 Feng et al. reported a 26% mortality resulting from thromboembolic pheno mena in their population of patients with ALamyloidosis. 49 Mechanisms of thromboembolism in cardiac amyloidosis include hypercoagulability, 51 endothelial dysfunction, endo myocardial damage, 52 direct myocardial toxic effects, 53 atrial systolic failure, 54 left ventricular diastolic dysfunction and stasis. 55 Although anticoagulation is indicated for secondary prevention, the decision should be balanced against the risk of hemorrhage to which these patients are predisposed. Bleeding in these patients is thought to be related to fragile blood ves sels resulting from amyloid deposition, as well as an acquired factor X deficiency which develops due to adsorption of the factor to the amyloid fibrils ( Figure 5 ). 56, 57 
Solid tumors
Although a variety of malignancies have been associated with arterial thromboembolic events, no single cancer type dominates. In their large cohort, Khorana et al. reported the association of arterial thromboembolic events with pros tate, lung and colon cancer. 2 Javid et al. studied a sample of 20 cancer patients who presented with arterial thrombosis. Amongst these patients, two (10%) had lung cancer, three (15%) had adenocarcinoma of unknown primary, three (15%) had colorectal cancer, five (25%) had breast cancer, two (10%) had ovarian cancer, one (5%) had leukemia, one (5%) had transitional cell carcinoma, one (5%) had mela noma, one (5%) had squamous cell carcinoma and one (5%) had nonHodgkin's lymphoma. 4 The mechanistic etiologies implicated in these cases included a hyperco agulable state of malignancy, peripheral embolization and direct tumor compression of the arterial walls.
Neurofibromatosis
Neurofibromatosis type I (NF1) is a genetic disorder associ ated with the development of neurofibromas, malignant nerve sheath tumors, myelogenous leukemia and pheochromocy toma. 58 NF1 is an autosomal dominant disorder characterized by mutations in the NF1 gene, which encodes neurofibromin, a GTPaseactivating protein that downregulates the p21ras cellular proto oncogene. 59 Neurofibromin has also been found in the vascular endothelial and smooth muscle cells. Abnormal or loss of neurofibromin function has been hypothesized to alter vascular histiogenesis, leading to NF1associated vascu lopathy 60 characterized by the development of arteriovenous malformations, aneurysms and stenosis. Intrinsic arterial wall lesions in patients with NF1 vasculopathy are thought to be related to spindle cell proliferation, 61 fibromuscular dysplasia, intimal thickening 62 and intramural nerve cell proliferation. 63 Clinical implications of NF1 vasculopathy include severe hypertension from renal artery stenosis and ruptured aortic aneurysms in addition to direct arterial compression by the neural tumor. 58 Treatment of NF1 vasculopathy depends on the patient's age and medical condition and the lesions' loca tions and characteristics; options include observation and monitoring for asymptomatic patients, and percutaneous intervention and surgical repair for symptomatic individuals.
Malignancy treatment-related thrombotic events Chemotherapy
Chemotherapeutic agents are now identified as an inde pendent risk factor for thrombosis in cancer patients. The true incidence of vascular events with these agents remains largely unknown, with most available data gener ated from case reports. In general, mechanisms for these events have included chemotherapyinduced expression of macrophagemonocyte tissue factor, 64 endogenous procoagulantanticoagulant mismatch, 65, 66 accentuated tumor and endothelial cell death, and cytokine release resulting in increased expression of tissue factor 67, 68 and enhanced endothelial cell reactivity to platelets. 69 Certain chemotherapy agents ( Table 3) have been associ ated with arterial thromboembolic events more than others: 5fluorouracil can decrease protein C levels and increase fibrinopeptide A levels 70 besides leading to endothelial damage and even endothelialindependent vasoconstriction via protein kinase C. 71 Gemcitabine has been associated with vascular events ranging from digital ischemia, VTE, thrombotic microangiopathy and systemic capillary leaks. 72 Cisplatin, a central component of several chemotherapeutic regimens, induces thrombosis by causing endothelial dam age, 73 activating platelets 74 and increasing monocyte tissue factor activity, 64 with a 12-17.6% risk 75 of strokes, recurrent peripheral arterial thromboembolic events and/or aortic thrombosis ( Figure 6 ). 76 Recently developed biologically targeted therapies such as bevacizumab, a vascular endothe lial growth factor (VEGF) inhibitor, have been associated with an increased risk of serious arterial thromboembolic events. 77, 78 Endothelial damage, reduction of endothelial renewal capacity, exposure of subendothelial collagen, subsequent tissue factor activation and overexpression of proinflammatory cyclooxygenase2 and Eselectin genes all lead to activation of the coagulation pathway, thereby causing intravascular thrombosis. [79] [80] [81] Scappaticci et al. reported the absolute rate of arterial thromboembolic events as 5.5 events per 100 personyears in their popula tion of patients concurrently receiving bevacizumab and chemotherapy. 82 Pereg and Lisher reported that lowdose aspirin effectively prevented cardiovascular complications in patients receiving bevacizumab who were 65 years or older with a prior history of cardiovascular ischemic events. 77 Sunitinib and sorafenib are two other VEGF receptor inhib itors with the mechanism of action involving tyrosine kinase inhibition. These agents have been shown to improve the clinical outcome of patients with different types of malignan cies (renal, hepatic, thyroid, gastrointestinal stromal tumors) and their use is expected to increase significantly in the future since these drugs are being assessed for activity in multiple other cancer types. A recent metaanalysis by Choueiri et al. found a significant increase in the risk of arterial thromboem bolic events with these agents (relative risk 3.03 (95% CI, 1.25-7.37; p = 0.015) compared with control patients. 83 More recently, Shahani et al. have reported a possible association between androgendeprivation therapy (GnRH agonists or antagonists, or androgen receptor antagonists used in conjunction with GnRH analogs) for prostate cancer and increased cardiovascular mortality via the development of metabolic syndrome, insulin resistance, diabetes and dys lipidemia. 84 Longterm prospective studies are needed to further elucidate such an association.
Radiation therapy
Arterial disease secondary to radiation therapy has been linked to accelerated atherosclerosis, with the risk depend ing on the radiation dose and technique, extent of vascula ture exposed and type of cancer. 85 Ionizing radiation has been proposed to cause oxidative stress resulting in acceler ated atherosclerosis; endothelial damage and fibrin deposi tion by activating the coagulation cascade; and accelerated transforming growth factor beta (TGFβ)mediated transfor mation of fibroblasts to fibrocytes, all of which predispose patients to arterial thromboembolic events. 86, 87 Prevention of radiationinduced atherosclerosis and subsequent thrombo sis involves reducing traditional atherosclerotic risk factors, with diet and lifestyle modifications including smoking ces sation. This is in addition to adequately managing diabetes, hypertension and dyslipidemia. 30 Pharmacologic interven tion includes lifelong antiplatelet therapy; additionally, statin therapy may be beneficial, given its antiinflammatory and antithrombotic effects on the irradiated endothelium. 88 Since surgical interventions may be difficult in scarred tissue, percutaneous angioplasty with stenting is becoming an attractive treatment modality when revascularization is indicated. For radiationinduced renal, iliac and femoral disease, balloon angioplasty with or without stenting has shown favorable results (Figure 7 ). [89] [90] [91] 
Supportive therapies related to arterial thromboembolism Erythropoetin (EPO)
Although most available data report the incidence of VTE with EPO use, EPO has also been implicated in the risk of arterial thromboembolic events in cancer patients, 92 espe cially when used in combination with chemotherapy. Studies have reported rates of arterial and venous thrombosis of 13-27%. 93, 94 Data regarding the role of altered protein C and S, factor VIII and von Willebrand factor levels secondary to EPO administration are inconsistent, 95 and proposed novel mechanisms point to increased creactive protein activity, nitric oxide and thrombinactivatable fibrinolysis inhibitor (TAFI) as the causative factors for EPOrelated thrombosis. 96 Blood and blood component transfusion Khorana 97, 98 increased circulating RBC mass and consequent vascular stasis; vasoconstriction due to nitric oxidedepleted RBCs; 99 and delivery of increased redoxactive iron, resulting in oxidative stress.
Suggested algorithm for evaluation of arterial thromboembolic events in patients with underlying malignancy
The clinical presentation and management of arterial throm boembolic events in general vary based on the arterial bed and the organ involved; the clinical spectrum includes stroke, myocardial infarction, and visceral and limb ischemia. The rest of the discussion in this review will focus mainly on the management of limb ischemia in patients with malignancy.
Standard evaluation for these patients should include a complete physical examination, complete blood count, basic metabolic panel, prothrombin time, partial thrombo plastin time and international normalized ratio. Initial eval uation should also include electrocardiography to identify arrhythmia, and echocardiography to detect a potential source of embolus. There should be a low threshold for per forming transesophageal echocardiography (TEE) because of the high prevalence of NBTE in this patient population. If these preliminary test results are unremarkable, computed tomographic angiography of the chest and abdomen may be necessary to detect a vascular source. In addition, carotid and subclavian artery duplex imaging should be performed in the setting of a suspected embolic event involving the central nervous system or affecting the upper extremities, respectively. Agitated saline contrast echocardiography and TEE are reasonable modalities for excluding an intra cardiac shunt in the presence of a suspected paradoxical embolism. When a thrombotic arterial ischemic event is suspected, further testing may be necessary to exclude the presence of APL antibody or tumorinduced blood vessel com pression. If the aforementioned workup is nondiagnostic, a chemotherapyinduced arterial thromboembolic event should be suspected (Figure 8 ).
It is not clear if extensive screening for cancer is justi fied in patients who present with an idiopathic arterial throm boembolic event. Oktar et al. recommended a moder ate screening strategy utilizing chest Xray, basic labora tory tests and abdominopelvic ultrasonography to search for occult cancer in patients presenting with idiopathic VTE and a more extensive screening strategy in patients with highrisk features for malignancy, such as thrombosis in unusual sites. 100 El Sakka et al. recommended chest Xray as a screening modality based on findings from their study, in which lung cancer was the predominant malig nancy in patients presenting with critical leg ischemia; 5 however, the absence of a single predominant malignancy in other studies does not support this recommendation.
Management (Figure 9)
Following the diagnosis of critical limb ischemia, urgent intervention is typically directed toward reversing isch emia and minimizing organ damage, followed by long term therapy and secondary prevention. The decision to use medical therapy versus a surgical or percutaneous approach to treat the acute event should be based on the Management of limbthreatening ischemia should in clude discontinuation of chemotherapy, early goaldirected therapy to reverse shock (if present) and anticoagulation with UFH or lowmolecularweight heparin and antiplatelet agents. Urgent surgical intervention is indicated if an embolic event is highly suspected. If the mechanism is not well defined, arteriography should determine the further course of action: percutaneous revascularization, embolec tomy, catheterbased thrombolysis or surgical bypass. Long term anticoagulation for primary and secondary prevention should be individualized and tailored to the patient's under lying pathologic process and balanced against his risk of bleeding. Table 4 summarizes the therapeutic interventions of potential benefit previously discussed separately with each clinical condition.
Prognosis
The prognosis of cancer patients presenting with arterial thromboembolic events is not well defined. It most likely depends on the patient's baseline condition, the underlying malignancy and the extent of organ damage. Khorana et al.
observed a high mortality rate following an arterial throm boembolic event in hospitalized cancer patients undergoing chemotherapy. 2 In patients with MPDs or radiationinduced atherosclerosis, a simple intervention like initiating anti platelet therapy and lipid management can significantly improve their outcome. Conversely, the outlook for patients with critical limb ischemia associated with solid tumors is poor, regardless of any intervention that might be tried. Arterial thrombosis in such settings can be agonizing for many of these patients. 4, 5 Increased awareness and vigi lance regarding this condition may lead to earlier detection and treatment, and thereby possibly alleviate some of the morbidities associated with these events.
Conclusion
Despite the significant morbidity and mortality rates asso ciated with arterial thromboembolic events in patients with cancer, there is a relative paucity of literature on this patho logy. Through this review we attempt to substantiate the cancer-arterial ischemic event relationship and pro vide suggested diagnostic and management guidelines, so as to improve the detection and treatment of this condition in clinical practice, and possibly alleviate some of the morbidity associated with it. Aspirin (for primary prevention in patients > 65 years old or with a history of cardiovascular events) NBTE, non-bacterial thrombotic endocarditis; PFO, patent foramen ovale; APLS, antiphospholipid antibody syndrome.
